2O), and reduced urine volume. Medullary osmolyte content were restored to control values (inositol, 232 Ϯ 12; sorbitol 32 Ϯ 6; GPC, 244 Ϯ 26; glycine betaine, 84 Ϯ 5 mmol/kg protein). Medullary urea rose to 2,122 Ϯ 305 mmol/kg protein. Reduced AQP2, AQP3, and urea transporter (UT-A1) expression was significantly reversed following amiloride therapy. Data presented here provide further understanding of how amiloride may substantially restore the lithiuminduced impaired renal concentrating mechanism. aquaporin; osmolytes; urea transporter LITHIUM IS A CHEAP AND EFFECTIVE drug which is widely used in the treatment of bipolar disorder (28). However, a confounding problem is the induction, in some 70% of patients, of overt polyuria and polydipsia (9,19,41), which in ϳ20% of sufferers become irreversible and lead ultimately to nephrogenic diabetes insipidus (NDI). A small percentage progresses to chronic renal failure (3,11,29). A large number of papers in recent years have demonstrated that the prime cause of the lithium-induced polyuria is the failure of vasopressin-mediated insertion of the water channel protein aquaporin-2 (AQP2) into the apical membranes of the principal cells of the renal collecting ducts (17,18,22,30). Lithium, entering the principal cells through the epithelial sodium channel (ENaC), inhibits the formation of cAMP (41), thus interrupting the chain of events in which the phosphorylation of PKA by cAMP leads, in turn, to the phosphorylation of one or more sites on AQP2, allowing translocation and insertion of AQP2 into the apical membrane (12). In the absence of apical AQP2, the normally increased water permeability of the membrane, induced by vasopressin, which would allow diffusion of water back into the renal interstitium down the established medullary osmotic gradient, does not occur. Additionally, reduction of cAMP levels, which normally act via the cAMP-response element to stimulate AQP2 production by binding to the promoter region of the AQP2 gene (23), leads to a decrease in AQP2 production. That lithium affects other routes of AQP2 insertion, however, is evidenced by the demonstration that lithiuminduced downregulation of AQP2 and the subsequent development of NDI can occur independently of adenylyl cyclase activity (20).In addition to its effects on AQP2, therapeutic doses of lithium reduce the abundance of the urea transporters UT-A1 and UT-B in the renal medulla of rats and also inhibit the vasopressin-mediated phosphorylation of UT-A1 (14), thus potentially contributing to the loss or reduction of the medullary osmotic gradient. However, there have been no studies to date which have documented the lithium-induced changes in renal medullary osmolyte concentrations.Lithium also has more widespread chronic renal effects. Microarray screening of gene expression in the renal medulla of lithium-treated compared with control rats demonstrated altered transcription and mRNA expression of a number of genes, including those involved in cellular proliferation and regulation of the actin cyto...